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Abstract The second mitochondria-derived activator of cas-
pase (Smac/DIABLO), vascular endothelial growth factor
(VEGF), and survivin are known to play a significant role in
the growth and development of numerous tumors. Serum con-
centrations of VEGF, survivin, and Smac/DIABLO were an-
alyzed in 92 patients with serous ovarian cancer and 94
healthy controls. Values were correlated with clinicopatholog-
ical characteristics and outcomes. The median pretreatment
serum VEGF and survivin levels in patients with serous ovar-
ian carcinoma were significantly higher, while Smac/DIABLO
levels were significantly lower than that in healthy controls.
Receiver operating characteristic (ROC) curve analysis showed
that the best cutoff point for VEGF was determined to be
345 pg/ml; with 83 % sensitivity and 65 % specificity. For
survivin, the cutoff point was 110 pg/ml and for Smac/
DIABLO was 75 pg/ml, with 82 and 62 % sensitivity and 43
and 87 % specificity, respectively. In the patients group, higher
VEGF and survivin levels and lower Smac/DIABLO levels in
sera were significantly associated with poorer overall survival
(OS) and disease-free survival (DFS). Preoperative measure-
ment of serum VEGF, survivin, and Smac/DIABLO may be
of help in early detection of serous ovarian cancer and may
provide important information about the patient’s outcome
and prognosis.
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Abbreviations
DFS Disease-free survival
ELISA Enzyme-linked immunosorbent assay
HR Hazard ratio
IAP Inhibitor of apoptosis
MDD Minimum detectable dose
OS Overall survival
ROC Receiver operating characteristic
Smac/
DIABLO
Second mitochondria-derived activator of
caspase
TNF-α Tumor necrosis factor alpha
VEGF Vascular endothelial growth factor
Introduction
Ovarian cancer is the most lethal cancer among gynecologic
malignancies. In 2012, it was estimated that 238,719 cases
were diagnosed and 151,905 women died from this disease
worldwide [1]. The estimated number of new ovarian cancer
cases in Europe in 2012 was 65,538 with 42,704 deaths [2]. In
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Poland, ovarian cancer is the second most frequent invasive
malignancy of the female genital tract after cancers of the
uterine corpus, with an estimated 3600 cases diagnosed annu-
ally. Approximately 2600 women die each year from ovarian
cancer, representing the most common cause of death among
women with gynecologic malignancies [3].
Approximately 90 % of malignant ovarian tumors arise
from the superficial epithelium which, even though similar
to the peritoneal mesothelium, is subject to malignant trans-
formation by genetic modifications that disrupt proliferation
and apoptosis [4]. In the group of apoptotic suppressors, in-
hibitors of apoptosis (IAP) family comprises survivin which is
capable of inhibiting the caspases cascade. Cellular apoptosis
is directed by two pathways. The extrinsic one is essential for
immune selection and inflammation. It commences by the
activation of cell death receptors, among them tumor necrosis
factor alpha (TNF-α) receptor, which is located at the cell
membrane. The intrinsic pathway is set off by toxic abuse
such as radiation or chemotherapy (DNA damaging and
antimicrotubule agents) [5]. While activating the intrinsic ap-
proach, mitochondrial permeability rises, which results in the
release of second mitochondria-derived activator of caspase
(Smac/DIABLO) (direct inhibitor of apoptosis-binding pro-
tein with LOw pI). This proapoptotic protein has a share in
both apoptotic pathways, intrinsic and extrinsic. Mature
Smac/DIABLO finds its place in mitochondria, and then an
apoptotic incentive is released into the cytosol. There, it binds
IAPs and neutralizes its inhibitory action on caspases [6].
Survivin is present in many different subcellular locations
such as the mitochondria, cytoplasm, and nucleus. However,
it has also been spotted in the extracellular space. Extracellular
volume can manage to mediate a prosurvival field effect due
to the fact that it is secreted by cancer cells and absorbed by
surrounding normal and modified cells. By linking extracel-
lular survivin’s capability to boost cellular proliferation, sur-
vival, and tumor cell invasion with a membrane-protective
trafficking modality, we can definitely provide additional sup-
port for the hypothesis that survivin plays a significant role in
the cancer cell growth and protection from therapeutic proce-
dures [7]. Survivin is suppressed by Smac/DIABLO which
causes the displacement of bound IAPs, which in turn is likely
to bind to and subdue caspase function [8].
Tumor growth relies upon its ability to switch the an-
giogenesis process. Tumoral angiogenesis is the conse-
quence of an imbalance between proangiogenic and
antiangiogenic factors. Especially, vascular endothelial
growth factor (VEGF) is expressed to a great extent in
the majority of ovarian cancers and its risen serum levels
as well as tumor VEGF levels have been found to be
independent markers of poor clinical outcome [9]. In
ovarian cancer, the importance of VEGF serum levels
and apoptosis markers is not clear. However, many reports
have indicated that an overexpression of these proteins in
tumor tissue of patients with ovarian cancer led to poor
prognosis [9, 10].
In the present study, VEGF, survivin, and Smac/DIABLO
levels were assessed in preoperative sera of patients with se-
rous ovarian carcinoma and the diagnostic as well as prognos-
tic impact content was estimated.
Material and methods
Patients
Ninety-two patients with histologically confirmed primary se-
rous ovarian carcinoma International Federation of Gynecol-
ogy and Obstetrics (FIGO) stages I–IV were enrolled in this
study. Patients were treated at the Department of Gynecology
of the Provincial Hospital in Bialystok, Poland, between 2005
and 2009, according to the international treatment guidelines
for ovarian cancer patients, including primary cytoreductive
surgery followed by platinum-containing chemotherapy [11].
All patients gave written informed consent. The protocol was
previously approved by the Bioethical Committee of theMed-
ical University of Bialystok.
Patient charts were reviewed to obtain data regarding age,
diagnosis, histology, grade, FIGO stage, presence or absence
of ascites, residual disease, operative findings, timing of re-
currence, and demise. Optimal cytoreduction was defined as
<1-cm residual disease after cytoreductive surgery. The pa-
thology for all of the patients with cancer was reviewed by
gynecologic pathologist. Five patients with stage IA ovarian
cancer did not receive adjuvant chemotherapy; all of the other
patients with invasive ovarian cancer were treated with adju-
vant chemotherapy. Response to treatment and diagnosis of
recurrence was determined according to RECIST criteria or
according to CA125 variations (GCIG-criteria) during follow-
up [12, 13]. Patients with recurrence during primary therapy
or within 6 months after primary therapy were defined as non-
responders [14].
Recurrence was proved by clinical examination and imag-
ing. CA125 was determined in most of the patients, but an
isolated increase in this tumor marker was not considered as
recurrence. At the end of the treatment, patients were regularly
evaluated for evidence of a new recurrence by clinical exam-
ination, transvaginal and transabdominal sonography, and
CA125 values (if elevated preoperative values applied). A
CT/MRI examination was performed if the examinations
mentioned above revealed pathological findings. Follow-up
data was completed until August 2014 at a median follow-
up of 44 months (range 1–106). Six patients were lost to
follow-up. The status of each patient was recorded as alive
without disease, alive with disease, dead of disease, or dead
from other causes.
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Laboratory methods
Blood was drawn at the preoperative visit, and serum was
stored at −80 °C until examination. The serum from 94
healthy volunteers (ages 21–72 years; median=54.7 years)
served as controls. Quantification of serum protein levels
was performed using an enzyme-linked immunosorbent assay
with a commercially available Human VEGF Quantikine®
enzyme-linked immunosorbent assay (ELISA) Kit and Hu-
man Survivin Quantikine® ELISA Kit, R&D Systems, Min-
neapolis, MN, USA (DVE00 and DSV00, respectively) and
Human Total SMAC/Diablo ELISA Kit Intracellular
Novatein Biosciences, Woburn, MA, USA (NR-E10804) ac-
cording to the manufacturer’s protocol using a microplate
LabSystemsMultiskan SpectrumMicroplate Reader (Thermo
Scientific,Waltham,MA, USA). Results were calculated from
a standard curve generated by a parametric logistic curve fit
and expressed in pg/ml of serum. To correct for variation in
platelet counts, VEGF per platelet (pg per 106 platelets) was
calculated by dividing serum VEGF concentration (pg/ml) by
the platelet count (×106/ml).
The minimum detectable dose (MDD) of survivin was
9.96 pg/ml. The assay ranged from 31.2 to 2000 pg/ml as
determined by the manufacturer. The MDD of VEGF ranged
from 31.2 to 2000 pg/ml. The mean MDD was 9 pg/ml. The
MDD of SMAC/Diablo was 5.4 pg/ml. The assay ranged from
56 to 3600 pg/ml. All test runs were duplicated. The patients’
clinical status was not known by the persons running the as-
says, and the results of these assays were disclosed to the
surgeons only after the patients’ disease status was recorded.
Statistical analyses
Continuous data are expressed as median (range) and were
compared using the Wilcoxon rank-sum test. Categorical data
were compared by the χ2 test or Fisher’s exact test. The
Kruskal-Wallis and Mann-Whitney U tests were used to eval-
uate differences between observations. Receiver operating
characteristic (ROC) curves were formed in an attempt to
determine the accuracy of VEGF, survivin, and smac/
DIABLO in detecting ovarian serous carcinoma. ROC curves
were used to establish the best cutoff value in this differentiation
using the Youden’s index. Sensitivity, specificity, and positive
and negative predictive values were calculated using this
threshold. Overall survival (OS) was measured as the time from
cancer diagnosis to death or date of last follow-up. For the
remission cohort analysis, OS was measured from the time of
complete remission. Disease-free survival (DFS) was defined
as the time from complete remission to treatment failure includ-
ing relapse, death, or date at last follow-up. Kaplan-Meier anal-
ysis was used to construct OS and DFS curves, and curves were
compared by the log-rank test. Cox univariate and multivariate
proportional hazard models were used to estimate the hazard
ratio for each marker and clinicopathological variables. p<0.05
was considered statistically significant. All statistical analyses
were calculated using Statistica software version 10.0PL
(StatSoft, Inc., StatSoft Polska Sp. z o.o., Poland).
Results
Patients’ average agewas 56 years (within range 32–76 years).
Thirty-three patients (35.9 %) developed low-grade (1 or 2)
disease, while 59 patients (64.1 %) had high-grade (3) disease.
Twenty-one patients (22.8 %) had low-stage (I or II) disease,
whereas 71 patients (77.2 %) developed advanced stage (III or
IV) disease. Sixty-one patients (66.3 %) underwent optimal
cytoreduction in comparison with 31 patients (33.7 %) who
underwent suboptimal cytoreductive surgery. Thirty-five pa-
tients (38.1 %) did not have any evidence of ascites, while 57
(61.9 %) had ascites present.
Pretreatment serum VEGF levels ranged from 160.6 to
1611.4 pg/ml, and its median value was 426.8 pg/ml for all
the patients who were tested. Serum VEGF levels in healthy
controls were also obtained. They ranged from 116.4 to
338.2 pg/ml, with an average value of 186.9 pg/ml. VEGF
levels were significantly higher in patients with serous ovarian
carcinoma, in comparison with controls (p<0.001). The me-
dian platelet count amounted to 224 (in the range of 114–
488)×106/ml. A significant correlation was found between
VEGF level and platelet count (rs=0.44, p=0.001). Median
VEGF level equalled 1.4 (the range between 0.14 and 4.89) pg
per 106 platelets. The serum survivin levels in the cancer pa-
tient group were found to be in the range from 56.6 to
188.4 pg/ml, with a median value of 112.4 pg/ml, whereas
in healthy controls, the range was 32.3 to 86.6 pg/ml and a
median value was 44.8 pg/ml, and it showed significant dif-
ference (p<0.001). Pretreatment Smac/DIABLO levels were
found to be between 56.2 and 328.8 pg/ml, with a median
value of 105.6 pg/ml. The level significantly plunged in the
serum of patients with cancer in comparison with healthy
controls (range from 61.3 to 704.6 pg/ml; median 247.2 pg/
ml) (p<0.001). The measurement findings of serum bio-
markers in normal healthy controls and serous ovarian
Table 1 Median concentrations of serum VEGF, survivin, and Smac/
DIABLO in serous ovarian carcinoma patients and control group





VEGF 426.8 (160.6–1611.4) 186.9 (116.4–338.2) <0.001
survivin 112.4 (56.6–188.4) 44.8 (32.3–86.6) <0.001
Smac/DIABLO 105.6 (56.2–328.8) 247.2 (61.3–704.6) <0.001
Tumor Biol. (2015) 36:4157–4165 4159
carcinoma patients are presented in Table 1. The distribution
of serum concentrations of VEGF, survivin, and Smac/
DIABLO in individual patient samples is demonstrated in
Fig. 1.
We examined the serum levels of VEGF, survivin, and
Smac/DIABLO in patients with serous ovarian carcinoma tak-
ing into account their age, grade, stage, level of cytoreduction,
and presence or absence of ascites. We presented the relation-
ships between these clinicopathological variables and the pro-
tein serum levels in Table 2. There was no significant correla-
tion between the levels of these three proteins and patients’
age (p>0.05). VEGF levels were much higher in patients with
the advanced tumor stage (p=0.013), grade (p=0.021), ascites
(p<0.001), and level of cytoreduction (p=0.009). Serum
levels of survivin rose in regard to the advanced tumor stage
(p=0.036), grade (p=0.032), ascites (p=0.002), and
cytoreduction (p=0.018). The serum levels of Smac/
DIABLO fell significantly with the tumor stage and grade
(p=0.015 and p=0.034, respectively). We did not find any
significant differences in Smac/DIABLO levels based on as-
cites or ability to achieve optimal level of cytoreduction (p=
0.112 and p=0.192, respectively) (Table 2).
We analyzed the group of patients for the relationship be-
tween the clinical outcome and the levels of VEGF, survivin,
and Smac/DIABLO. Kaplan-Meier analyses for OS and DFS
were carried out by means of the median levels of proteins as
Fig. 1 The distribution of serum concentrations of a VEGF, b survivin, and c Smac/DIABLO; individual patient samples
Table 2 Correlation between the VEGF, survivin, Smac/DIABLO, and clinicopathological parameters
Parameter VEGF (pg/ml) survivin (pg/ml) Smac/DIABLO (pg/ml)
Median (range) p Median (range) p Median (range) p
Age
<56 492.6 (160.6–855.2) 0.063 87.2 (56.3–146.8) 0.214 117.8 (68.3–328.6) 0.262
≥56 538.4 (212.4–1611.5) 125.2 (58.4–188.4) 97.8 (57.3–268.4)
Grade
1–2 413.8 (160.6–888.5) 0.021 73.2 (56.3–142.4) 0.032 124.3 (64.1–328.6) 0.034
3 559.7 (265.5–1611.5) 131.4 (62.3–188.4) 87.2 (57.3–284.8)
Stage
I–II 383.6 (160.6–764.8) 0.013 82.2 (56.3–148.6) 0.036 134.8 (68.8–328.6) 0.015
III–IV 598.4 (448.2–1611.5) 139.5 (64.6–188.4) 74.2 (57.3–276.2)
Cytoreduction
≤1 cm 346.2 (160.6–887.4) 0.009 84.2 (56.3–138.8) 0.018 114.4 (58.9–328.6) 0.192
>1 cm 564.2 (269.6–1611.5) 149.4 (66.2–188.4) 94.8 (57.3–245.4)
Ascites
Absent 287.8 (160.6–754.8) <0.001 76.2 (56.3–145.4) 0.002 116.8 (71.3–328.6) 0.112
Present 574.2 (264.5–1611.5) 142.8 (59.2–188.4) 97.6 (57.3–258.2)
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the cutoff for the definition of the subgroups. Higher serum
VEGF and survivin or lower Smac/DIABLO levels
corresponded with poor prognosis (Fig. 2). The OS probabil-
ities at 5 years of the high VEGF (21 %) and survivin (18 %)
group were notably lower than those of the low VEGF (59 %;
p<0.001) and survivin (61 %; p<0.001) group (Fig. 2a, b,
respectively). The patients in the low Smac/DIABLO group
developed significantly shorter OS than those in the high
Smac/DIABLO group (p=0.015; Fig. 2c). The probabilities
of DFS at 5 years in the low VEGF and survivin group were
62 and 63 %, respectively, while in the high VEGF and
survivin group equalled 24 and 22 %, respectively (p<0.001;
Fig. 2d, e). There was also an apparent association between low
Smac/DIABLO levels and a reduced DFS (p=0.034) (Fig. 2f).
Univariate analysis of the clinicopathological parameters
proved that stage, grade, residual tumor, and ascites were
found to correlate with a shorter DFS andOS in serous ovarian
cancer patients (Table 3).
In multivariate analysis of the clinicopathological parame-
ters, stage and tumor grade remained to be seen as indepen-
dent predictors of DFS in ovarian cancer patients. Stage and
residual tumor turned out to be independent predictors of OS.
Fig. 2 Kaplan-Meier analysis for a–c OS and d–f for DFS according to VEGF, survivin, and Smac/DIABLO serum levels. In each set, different
subgroups were plotted according to the cutoff value of VEGF, survivin, and Smac/DIABLO levels defined as the median of the set
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Multivariate analysis identified raised serum VEGF as well as
survivin and decreased serum Smac/DIABLO levels as inde-
pendent risk factors for the prognosis (Table 4).
Receiver operating characteristic (ROC) curve analyses un-
veiled that the serum level of VEGFwas a useful biomarker to
be used for distinguishing patients with serous ovarian carci-
noma from controls within ROC curve areas of 0.787 (95 %
CI=0.659–0.839). At the cutoff value of 345 pg/ml for VEGF,
the sensitivity was 83 %, and the specificity was 65 %
(Fig. 3a). The ROC curve areas for survivin and Smac/
DIABLO equalled 0.698 (95 % CI=0.577–0.772) and 0.671
(95 % CI=0.568–0.764), respectively. At the cutoff value of
110 pg/ml for survivin and 75 pg/ml for Smac/DIABLO, the
sensitivity amounted to 82 and 62 %, while specificity
amounted to 43 and 87 % (Fig. 3b, c).
Discussion
Based on recent studies, it can be concluded that the inhibition
of apoptosis, rather than enhanced cellular proliferation, is
supposed to be a critical feature that might lead to ovarian
carcinogenesis. Not to mention other regulators of ovarian
cancer apoptosis, preoccupation has recently been addressed
to survivin, a multifunctional member of the IAP gene family
that both neutralizes cell death and regulates mitotic progres-
sion. Selective overexpression of survivin has been connected
with higher tumor grade, advanced disease stage, rapid tumor
progression, short patient survival, as well as resistance to
therapy in patients with various malignancies [15, 16]. Some
articles showed that survivin is a novel growth factor-
inducible protective gene expressed by endothelial cells dur-
ing angiogenesis and that survivin was initiated by VEGF via
a PI3 K/Akt pathway [17].
Although platelet counts may have a great impact on serum
VEGF levels, it has been shown that platelet-derived VEGF
also reflects the biology of cancer cells and that serum appears
to be more useful than plasma for the measurement of circu-
lating VEGF in cancer patients for prognosis [18, 19]. That is
why, in the present study, serum samples were used. Upon
VEGF discovery till 2014, nine studies which directly linked
preoperative serum levels of VEGF with ovarian cancer out-
come were published. Unfortunately, due to the heterogeneity
of these studies as well as lacking or incomplete information,
there is no possibility to pool data and to perform a meta-
analysis so as to receive indisputable indications referring to
Table 3 Univariate analyses of
disease-free and overall survival
at 5 years
Disease-free survival (DFS) Overall survival (OS)
HR 95 % CI p HR 95 % CI p
VEGF (low vs. high) 2.189 1.284–3.136 <0.001 2.111 1.188–4.943 <0.001
survivin (low vs. high) 2.054 1.182–3.025 <0.001 1.731 1.642–2.843 <0.001
Smac/DIABLO (low vs. high) 1.776 1.044–2.982 0.034 1.442 1.214–2.806 0.015
Age (<56 vs. ≥56) 0.814 0.528–1.082 0.442 0.852 0.584–1.681 0.228
Stage (I/II vs. III/IV) 9.889 2.646–41.431 <0.001 10.618 2.672–42.678 <0.001
Grade (1–2 vs. 3) 1.832 0.732–2.944 0.012 1.824 0.727–2.249 0.034
Cytoreduction (≤1 vs. >1 cm) 2.596 1.382–4.038 0.003 2.289 1.076–4.828 0.006
Ascites (absence vs. presence) 2.687 1.428–4.252 0.011 2.262 1.123–3.712 0.004





HR 95 % CI p HR 95 % CI p
VEGF (low vs. high) 2.648 1.142–3.663 <0.001 2.340 1.186–4.643 <0.001
survivin (low vs. high) 2.073 1.078–3.739 0.001 2.086 1.109–3.942 0.004
Smac/DIABLO (low vs. high) 2.081 1.146–2.866 0.023 2.146 1.208–2.988 0.044
Stage (I/II vs. III/IV) 9.032 2.743–40.352 <0.001 9.936 2.748–41.122 <0.001
Grade (1–2 vs. 3) 1.986 0.746–2.864 0.032 0.842 0.458–1.523 0.528
Cytoreduction (≤1 vs. >1 cm) 0.863 0.534–1.428 0.124 2.756 1.449–5.229 0.002
Ascites (absence vs. presence) 0.765 0.438–1.226 0.114 0.842 0.528–1.523 0.211
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serum VEGF’s prognostic value. Even though seven [20–26]
out of nine studies used the same VEGF assay, one [21] of
them measured significantly lower VEGF values in ovarian
cancer patients. Last but not the least, widely differing VEGF
cutoff values (ranging from 100 to 826 pg/ml) were selected
for univariate and multivariate analysis, depending on the sta-
tistical methods used for the analysis. Furthermore, seven out
of eight studies, concerning the relation between VEGF and
FIGO stage, emphasized that VEGF concentrations measured
in sera were not connected with staging. In our study, the
median level of VEGF in patients with serous ovarian cancer
was significantly higher than that in normal volunteers, and
also the median serum level of VEGF inversely correlated
both with the progression of the stage and the increase of the
grade of cancer. That may indicate that the effects promoted
by VEGF are a continuous process and are independent of the
clinical progression of the disease [27]. Previous studies relat-
ing serum VEGF levels to survival provided mixed results.
Some studies found VEGF to be an independent prognostic
factor by means of multivariate analysis [20, 22]. Other stud-
ies, on the other hand, did not find a correlation between
serum VEGF and survival [25]. In our present study, preoper-
ative serum VEGF levels were an independent prognostic
factor for ovarian serous carcinoma. Therefore, in this exam-
ined uniform group, VEGF turns out to be the best prognostic
marker for OS in comparison with the established prognostic
variables such as stage and residual tumor size and appears to
be an independent prognostic factor not only for DFS but also
for tumor stage and grade.
Up till now the majority of the studies investigating the
influence of survivin on the prognosis of ovarian cancers fo-
cused on tissue expression and discovered that survivin over-
expression in tumors is associated with advanced disease
stage, poorer survival, and chemotherapy or radiation resis-
tance [28–31]. This is why it appears that the serum level of
survivin might be advantageous in both the diagnosis and
prognosis of cancer. Our results suggest that survivin is
connected with progression and recurrence of serous ovarian
cancer. In the present study, high serum levels of survivin were
in close correlation with advanced stage, grade, presence of
ascites, and level of cytoreduction. Previous studies revealed
that serum survivin levels are associated with peritoneal me-
tastasis of serous ovarian cancer [15], nodal involvement in
breast cancer [32], advanced stages of head and neck cancer
[33], and prostate cancer [34]. Moreover, survivin may sup-
press apoptosis by facilitating sequestration of the
Smac/DIABLO, which antagonizes the inhibitory function
of XIAP [35]. The role of this protein during carcinogenesis
must still be investigated [36]. Nevertheless, Smac/DIABLO
mRNA levels were found to be notably lower in lung cancers
when compared to normal tissues. Patients with low Smac/
DIABLO mRNA levels were shown to have worse prognosis
[37].
Mizutani et al. [38] reported for the first time that Smac/
DIABLO can be found in the serum and that the average
serum level of this protein inversely correlated not only with
the progression of the stage but also with the rise of the degree
of bladder cancer. The present study has demonstrated for the
first time that the serum level of Smac/DIABLO predicted the
clinical outcome and that the lower levels were associated
with poor prognosis in patients with serous ovarian cancer.
Although Smac/DIABLO is not a secretory molecule, it is
possible that it could be detected in serum. Its presence in
the circulation may be due to the physiological cell death of
normal tissues and cell death of tumor cells. In more aggres-
sive tumors, the less apoptotic cell death occurs and less
Smac/DIABLO is freed into the circulation. This finding is
in accord with Mizutani et al. [38] hypothesis, but further
studies are essential to determine the origin of this protein.
To conclude, the results of this study indicate that preoper-
ative measurement of serum VEGF, survivin, and Smac/
DIABLO may be of great help in early detection of serous
ovarian cancer but also may provide important information
about the patients’ outcome and prognosis. These precursory
Fig. 3 ROC curves of aVEGF, b survivin, and c Smac/DIABLO. ROC curves were derived by plotting the relationship between the specificity and the
sensitivity at various cutoff levels. The area under the curve was 0.787 for VEGF, 0.698 for survivin, and 0.671 for Smac/DIABLO
Tumor Biol. (2015) 36:4157–4165 4163
findings on the diagnostic and prognostic potential of VEGF,
survivin, and Smac/DIABLO in serous ovarian carcinoma
should now be confirmed in large prospective trials.
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